Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Spie Presentation on PDT Optimization

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Apr 07, 2022 7:56pm

142 Views

Post# 34586361

RE:Spie Presentation on PDT Optimization

Eoganacht ... Nice catch. Thanks for sharing.

Nice to see that Theralase is contributing to Dr. Lilge's advancements.

In the paper, we've seen 5 cancer indications:

- bladder
- head and neck (tongue)
- brain
- pancreas
- lung

Sounds like we could hear about Prof. McFarland super PDCs one day for pancreas and head&neck. Lets recall that TLT has tested for 6 indications so far involving whether TLD_1433-Rutherrin and TLD-1633. Pancreas was not among these 6 indications.

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth